{"transactions":[{"id":3665652,"issuer":{"id":3496,"kind":"organization","name":"GLOBUS MEDICAL INC","symbol":"GMED"},"owners":[{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":1,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy Class A Common Stock)","published_at":"2019-02-11T21:50:02.000Z","date":"2019-01-22","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options were granted on January 22, 2019, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on January 1, 2020, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months."}],"balance_after":25000,"derivative":{"exercise_price":43.58,"expiration_date":"2029-01-22","underlying":"Class A Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-19-008994","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1237831/000120919119008994/doc4.xml","form_type":"4"}},{"id":3801178,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":15491,"kind":"organization","name":"Clarus Lifesciences III, L.P.","position":1,"cik":"0001597143","reported_name":"Clarus Lifesciences III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15492,"kind":"organization","name":"Clarus Ventures III GP, L.P.","position":2,"cik":"0001620148","reported_name":"Clarus Ventures III GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163261,"kind":"organization","name":"Clarus Ventures III, LLC","position":3,"cik":"0001664942","reported_name":"Clarus Ventures III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":4,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":5,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":6,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74247,"kind":"person","name":"Requadt Scott","position":7,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":8,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Tranche B Convertible Preferred Stock","published_at":"2018-10-02T21:36:20.000Z","date":"2018-09-28","kind":"exercise","acquired":false,"shares":8552024,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are held directly by Clarus Lifesciences III, L.P. (\"Clarus III\"). Clarus Ventures III GP, L.P. (\"Clarus III GP\") is the sole general partner of Clarus III. Clarus Ventures III, LLC (\"Clarus III GP LLC\") is the sole general partner of Clarus III GP. Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon, and Kurt Wheeler are the managing directors of Clarus III GP LLC (the \"Managing Members\"). Each of Clarus III GP, Clarus III GP LLC and the Managing Members may be deemed to beneficially own the securities held by Clarus III. Each of Clarus III GP, Clarus III GP LLC and the Managing Members disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":412583},"source":{"system":"sec-edgar","filing":"0001209191-18-053534","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1431403/000120919118053534/doc4.xml","form_type":"4"}},{"id":3801177,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":15491,"kind":"organization","name":"Clarus Lifesciences III, L.P.","position":1,"cik":"0001597143","reported_name":"Clarus Lifesciences III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15492,"kind":"organization","name":"Clarus Ventures III GP, L.P.","position":2,"cik":"0001620148","reported_name":"Clarus Ventures III GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163261,"kind":"organization","name":"Clarus Ventures III, LLC","position":3,"cik":"0001664942","reported_name":"Clarus Ventures III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":4,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":5,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":6,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74247,"kind":"person","name":"Requadt Scott","position":7,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":8,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Tranche A Convertible Preferred Stock","published_at":"2018-10-02T21:36:20.000Z","date":"2018-09-28","kind":"exercise","acquired":false,"shares":6702213,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are held directly by Clarus Lifesciences III, L.P. (\"Clarus III\"). Clarus Ventures III GP, L.P. (\"Clarus III GP\") is the sole general partner of Clarus III. Clarus Ventures III, LLC (\"Clarus III GP LLC\") is the sole general partner of Clarus III GP. Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon, and Kurt Wheeler are the managing directors of Clarus III GP LLC (the \"Managing Members\"). Each of Clarus III GP, Clarus III GP LLC and the Managing Members may be deemed to beneficially own the securities held by Clarus III. Each of Clarus III GP, Clarus III GP LLC and the Managing Members disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":323341},"source":{"system":"sec-edgar","filing":"0001209191-18-053534","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1431403/000120919118053534/doc4.xml","form_type":"4"}},{"id":3801176,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":15491,"kind":"organization","name":"Clarus Lifesciences III, L.P.","position":1,"cik":"0001597143","reported_name":"Clarus Lifesciences III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15492,"kind":"organization","name":"Clarus Ventures III GP, L.P.","position":2,"cik":"0001620148","reported_name":"Clarus Ventures III GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163261,"kind":"organization","name":"Clarus Ventures III, LLC","position":3,"cik":"0001664942","reported_name":"Clarus Ventures III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":4,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":5,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":6,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74247,"kind":"person","name":"Requadt Scott","position":7,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":8,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2018-10-02T21:36:20.000Z","date":"2018-09-28","kind":"exercise","acquired":false,"shares":7500000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are held directly by Clarus Lifesciences III, L.P. (\"Clarus III\"). Clarus Ventures III GP, L.P. (\"Clarus III GP\") is the sole general partner of Clarus III. Clarus Ventures III, LLC (\"Clarus III GP LLC\") is the sole general partner of Clarus III GP. Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon, and Kurt Wheeler are the managing directors of Clarus III GP LLC (the \"Managing Members\"). Each of Clarus III GP, Clarus III GP LLC and the Managing Members may be deemed to beneficially own the securities held by Clarus III. Each of Clarus III GP, Clarus III GP LLC and the Managing Members disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":361829},"source":{"system":"sec-edgar","filing":"0001209191-18-053534","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1431403/000120919118053534/doc4.xml","form_type":"4"}},{"id":3801175,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":15491,"kind":"organization","name":"Clarus Lifesciences III, L.P.","position":1,"cik":"0001597143","reported_name":"Clarus Lifesciences III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15492,"kind":"organization","name":"Clarus Ventures III GP, L.P.","position":2,"cik":"0001620148","reported_name":"Clarus Ventures III GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163261,"kind":"organization","name":"Clarus Ventures III, LLC","position":3,"cik":"0001664942","reported_name":"Clarus Ventures III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":4,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":5,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":6,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74247,"kind":"person","name":"Requadt Scott","position":7,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":8,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-02T21:36:20.000Z","date":"2018-09-28","kind":"purchase","acquired":true,"shares":453395,"price":15,"value":6800925.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are held directly by Clarus Lifesciences III, L.P. (\"Clarus III\"). Clarus Ventures III GP, L.P. (\"Clarus III GP\") is the sole general partner of Clarus III. Clarus Ventures III, LLC (\"Clarus III GP LLC\") is the sole general partner of Clarus III GP. Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon, and Kurt Wheeler are the managing directors of Clarus III GP LLC (the \"Managing Members\"). Each of Clarus III GP, Clarus III GP LLC and the Managing Members may be deemed to beneficially own the securities held by Clarus III. Each of Clarus III GP, Clarus III GP LLC and the Managing Members disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein."}],"balance_after":1623405,"source":{"system":"sec-edgar","filing":"0001209191-18-053534","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1431403/000120919118053534/doc4.xml","form_type":"4"}},{"id":3801174,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":15491,"kind":"organization","name":"Clarus Lifesciences III, L.P.","position":1,"cik":"0001597143","reported_name":"Clarus Lifesciences III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15492,"kind":"organization","name":"Clarus Ventures III GP, L.P.","position":2,"cik":"0001620148","reported_name":"Clarus Ventures III GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163261,"kind":"organization","name":"Clarus Ventures III, LLC","position":3,"cik":"0001664942","reported_name":"Clarus Ventures III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":4,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":5,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":6,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74247,"kind":"person","name":"Requadt Scott","position":7,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":8,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-02T21:36:20.000Z","date":"2018-09-28","kind":"exercise","acquired":true,"shares":412583,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"This number includes an aggregate of 72,257 shares of Common Stock received upon the conversion of the Issuer's Preferred Stock as payment of the accrued dividends through September 27, 2018. No dividends will accrue after September 27, 2018."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are held directly by Clarus Lifesciences III, L.P. (\"Clarus III\"). Clarus Ventures III GP, L.P. (\"Clarus III GP\") is the sole general partner of Clarus III. Clarus Ventures III, LLC (\"Clarus III GP LLC\") is the sole general partner of Clarus III GP. Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon, and Kurt Wheeler are the managing directors of Clarus III GP LLC (the \"Managing Members\"). Each of Clarus III GP, Clarus III GP LLC and the Managing Members may be deemed to beneficially own the securities held by Clarus III. Each of Clarus III GP, Clarus III GP LLC and the Managing Members disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein."}],"balance_after":1170010,"source":{"system":"sec-edgar","filing":"0001209191-18-053534","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1431403/000120919118053534/doc4.xml","form_type":"4"}},{"id":3801173,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":15491,"kind":"organization","name":"Clarus Lifesciences III, L.P.","position":1,"cik":"0001597143","reported_name":"Clarus Lifesciences III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15492,"kind":"organization","name":"Clarus Ventures III GP, L.P.","position":2,"cik":"0001620148","reported_name":"Clarus Ventures III GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163261,"kind":"organization","name":"Clarus Ventures III, LLC","position":3,"cik":"0001664942","reported_name":"Clarus Ventures III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":4,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":5,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":6,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74247,"kind":"person","name":"Requadt Scott","position":7,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":8,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-02T21:36:20.000Z","date":"2018-09-28","kind":"exercise","acquired":true,"shares":323341,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are held directly by Clarus Lifesciences III, L.P. (\"Clarus III\"). Clarus Ventures III GP, L.P. (\"Clarus III GP\") is the sole general partner of Clarus III. Clarus Ventures III, LLC (\"Clarus III GP LLC\") is the sole general partner of Clarus III GP. Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon, and Kurt Wheeler are the managing directors of Clarus III GP LLC (the \"Managing Members\"). Each of Clarus III GP, Clarus III GP LLC and the Managing Members may be deemed to beneficially own the securities held by Clarus III. Each of Clarus III GP, Clarus III GP LLC and the Managing Members disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein."}],"balance_after":685170,"source":{"system":"sec-edgar","filing":"0001209191-18-053534","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1431403/000120919118053534/doc4.xml","form_type":"4"}},{"id":3801172,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":15491,"kind":"organization","name":"Clarus Lifesciences III, L.P.","position":1,"cik":"0001597143","reported_name":"Clarus Lifesciences III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15492,"kind":"organization","name":"Clarus Ventures III GP, L.P.","position":2,"cik":"0001620148","reported_name":"Clarus Ventures III GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163261,"kind":"organization","name":"Clarus Ventures III, LLC","position":3,"cik":"0001664942","reported_name":"Clarus Ventures III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":4,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":5,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":6,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74247,"kind":"person","name":"Requadt Scott","position":7,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":8,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-02T21:36:20.000Z","date":"2018-09-28","kind":"exercise","acquired":true,"shares":361829,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are held directly by Clarus Lifesciences III, L.P. (\"Clarus III\"). Clarus Ventures III GP, L.P. (\"Clarus III GP\") is the sole general partner of Clarus III. Clarus Ventures III, LLC (\"Clarus III GP LLC\") is the sole general partner of Clarus III GP. Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon, and Kurt Wheeler are the managing directors of Clarus III GP LLC (the \"Managing Members\"). Each of Clarus III GP, Clarus III GP LLC and the Managing Members may be deemed to beneficially own the securities held by Clarus III. Each of Clarus III GP, Clarus III GP LLC and the Managing Members disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein."}],"balance_after":361829,"source":{"system":"sec-edgar","filing":"0001209191-18-053534","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1431403/000120919118053534/doc4.xml","form_type":"4"}},{"id":3878867,"issuer":{"id":16035,"kind":"organization","name":"Forty Seven, Inc.","symbol":"FTSV"},"owners":[{"id":15491,"kind":"organization","name":"Clarus Lifesciences III, L.P.","position":1,"cik":"0001597143","reported_name":"Clarus Lifesciences III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15492,"kind":"organization","name":"Clarus Ventures III GP, L.P.","position":2,"cik":"0001620148","reported_name":"Clarus Ventures III GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163261,"kind":"organization","name":"Clarus Ventures III, LLC","position":3,"cik":"0001664942","reported_name":"Clarus Ventures III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":4,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139654,"kind":"person","name":"GALAKATOS NICHOLAS","position":5,"cik":"0001252522","reported_name":"GALAKATOS NICHOLAS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":6,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":7,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74247,"kind":"person","name":"Requadt Scott","position":8,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":9,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2018-07-02T17:14:14.000Z","date":"2018-07-02","kind":"exercise","acquired":false,"shares":1922682,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Clarus Ventures III GP, LP, or GPLP, as the sole general partner of Clarus Lifesciences III, LP, or Clarus, may be deemed to beneficially own certain of the shares held by Clarus. GPLP disclaims beneficial ownership of all shares held by Clarus in which the GPLP does not have a pecuniary interest. Clarus Ventures III, LLC, or GPLLC, as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. GPLLC disclaims beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest. Each of Dennis Henner, Nicholas Galakatos, Robert Liptak, Nicholas Simon, Scott Requadt and Kurt Wheeler, as individual managing directors of GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Dr. Henner and Messrs. Galakatos, Liptak, Simon, Requadt and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which they do not have an actual pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1922682},"source":{"system":"sec-edgar","filing":"0001209191-18-040426","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1667633/000120919118040426/doc4.xml","form_type":"4"}},{"id":3878866,"issuer":{"id":16035,"kind":"organization","name":"Forty Seven, Inc.","symbol":"FTSV"},"owners":[{"id":15491,"kind":"organization","name":"Clarus Lifesciences III, L.P.","position":1,"cik":"0001597143","reported_name":"Clarus Lifesciences III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15492,"kind":"organization","name":"Clarus Ventures III GP, L.P.","position":2,"cik":"0001620148","reported_name":"Clarus Ventures III GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163261,"kind":"organization","name":"Clarus Ventures III, LLC","position":3,"cik":"0001664942","reported_name":"Clarus Ventures III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":4,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139654,"kind":"person","name":"GALAKATOS NICHOLAS","position":5,"cik":"0001252522","reported_name":"GALAKATOS NICHOLAS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":6,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":7,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74247,"kind":"person","name":"Requadt Scott","position":8,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":9,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Preferred Stock","published_at":"2018-07-02T17:14:14.000Z","date":"2018-07-02","kind":"exercise","acquired":false,"shares":755780,"ownership":{"direct":false,"nature":"See foonote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Clarus Ventures III GP, LP, or GPLP, as the sole general partner of Clarus Lifesciences III, LP, or Clarus, may be deemed to beneficially own certain of the shares held by Clarus. GPLP disclaims beneficial ownership of all shares held by Clarus in which the GPLP does not have a pecuniary interest. Clarus Ventures III, LLC, or GPLLC, as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. GPLLC disclaims beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest. Each of Dennis Henner, Nicholas Galakatos, Robert Liptak, Nicholas Simon, Scott Requadt and Kurt Wheeler, as individual managing directors of GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Dr. Henner and Messrs. Galakatos, Liptak, Simon, Requadt and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which they do not have an actual pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":755780},"source":{"system":"sec-edgar","filing":"0001209191-18-040426","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1667633/000120919118040426/doc4.xml","form_type":"4"}},{"id":3878865,"issuer":{"id":16035,"kind":"organization","name":"Forty Seven, Inc.","symbol":"FTSV"},"owners":[{"id":15491,"kind":"organization","name":"Clarus Lifesciences III, L.P.","position":1,"cik":"0001597143","reported_name":"Clarus Lifesciences III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15492,"kind":"organization","name":"Clarus Ventures III GP, L.P.","position":2,"cik":"0001620148","reported_name":"Clarus Ventures III GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163261,"kind":"organization","name":"Clarus Ventures III, LLC","position":3,"cik":"0001664942","reported_name":"Clarus Ventures III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":4,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139654,"kind":"person","name":"GALAKATOS NICHOLAS","position":5,"cik":"0001252522","reported_name":"GALAKATOS NICHOLAS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":6,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":7,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74247,"kind":"person","name":"Requadt Scott","position":8,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":9,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Preferred Stock","published_at":"2018-07-02T17:14:14.000Z","date":"2018-07-02","kind":"exercise","acquired":false,"shares":938489,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Clarus Ventures III GP, LP, or GPLP, as the sole general partner of Clarus Lifesciences III, LP, or Clarus, may be deemed to beneficially own certain of the shares held by Clarus. GPLP disclaims beneficial ownership of all shares held by Clarus in which the GPLP does not have a pecuniary interest. Clarus Ventures III, LLC, or GPLLC, as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. GPLLC disclaims beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest. Each of Dennis Henner, Nicholas Galakatos, Robert Liptak, Nicholas Simon, Scott Requadt and Kurt Wheeler, as individual managing directors of GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Dr. Henner and Messrs. Galakatos, Liptak, Simon, Requadt and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which they do not have an actual pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":938489},"source":{"system":"sec-edgar","filing":"0001209191-18-040426","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1667633/000120919118040426/doc4.xml","form_type":"4"}},{"id":3878864,"issuer":{"id":16035,"kind":"organization","name":"Forty Seven, Inc.","symbol":"FTSV"},"owners":[{"id":15491,"kind":"organization","name":"Clarus Lifesciences III, L.P.","position":1,"cik":"0001597143","reported_name":"Clarus Lifesciences III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15492,"kind":"organization","name":"Clarus Ventures III GP, L.P.","position":2,"cik":"0001620148","reported_name":"Clarus Ventures III GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163261,"kind":"organization","name":"Clarus Ventures III, LLC","position":3,"cik":"0001664942","reported_name":"Clarus Ventures III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":4,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139654,"kind":"person","name":"GALAKATOS NICHOLAS","position":5,"cik":"0001252522","reported_name":"GALAKATOS NICHOLAS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":6,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":7,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74247,"kind":"person","name":"Requadt Scott","position":8,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":9,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-07-02T17:14:14.000Z","date":"2018-07-02","kind":"purchase","acquired":true,"shares":200000,"price":16,"value":3200000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Clarus Ventures III GP, LP, or GPLP, as the sole general partner of Clarus Lifesciences III, LP, or Clarus, may be deemed to beneficially own certain of the shares held by Clarus. GPLP disclaims beneficial ownership of all shares held by Clarus in which the GPLP does not have a pecuniary interest. Clarus Ventures III, LLC, or GPLLC, as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. GPLLC disclaims beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest. Each of Dennis Henner, Nicholas Galakatos, Robert Liptak, Nicholas Simon, Scott Requadt and Kurt Wheeler, as individual managing directors of GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Dr. Henner and Messrs. Galakatos, Liptak, Simon, Requadt and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which they do not have an actual pecuniary interest."}],"balance_after":3816951,"source":{"system":"sec-edgar","filing":"0001209191-18-040426","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1667633/000120919118040426/doc4.xml","form_type":"4"}},{"id":3878863,"issuer":{"id":16035,"kind":"organization","name":"Forty Seven, Inc.","symbol":"FTSV"},"owners":[{"id":15491,"kind":"organization","name":"Clarus Lifesciences III, L.P.","position":1,"cik":"0001597143","reported_name":"Clarus Lifesciences III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15492,"kind":"organization","name":"Clarus Ventures III GP, L.P.","position":2,"cik":"0001620148","reported_name":"Clarus Ventures III GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163261,"kind":"organization","name":"Clarus Ventures III, LLC","position":3,"cik":"0001664942","reported_name":"Clarus Ventures III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":4,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139654,"kind":"person","name":"GALAKATOS NICHOLAS","position":5,"cik":"0001252522","reported_name":"GALAKATOS NICHOLAS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":6,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":7,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74247,"kind":"person","name":"Requadt Scott","position":8,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":9,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-07-02T17:14:14.000Z","date":"2018-07-02","kind":"exercise","acquired":true,"shares":1922682,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Clarus Ventures III GP, LP, or GPLP, as the sole general partner of Clarus Lifesciences III, LP, or Clarus, may be deemed to beneficially own certain of the shares held by Clarus. GPLP disclaims beneficial ownership of all shares held by Clarus in which the GPLP does not have a pecuniary interest. Clarus Ventures III, LLC, or GPLLC, as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. GPLLC disclaims beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest. Each of Dennis Henner, Nicholas Galakatos, Robert Liptak, Nicholas Simon, Scott Requadt and Kurt Wheeler, as individual managing directors of GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Dr. Henner and Messrs. Galakatos, Liptak, Simon, Requadt and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which they do not have an actual pecuniary interest."}],"balance_after":3616951,"source":{"system":"sec-edgar","filing":"0001209191-18-040426","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1667633/000120919118040426/doc4.xml","form_type":"4"}},{"id":3878862,"issuer":{"id":16035,"kind":"organization","name":"Forty Seven, Inc.","symbol":"FTSV"},"owners":[{"id":15491,"kind":"organization","name":"Clarus Lifesciences III, L.P.","position":1,"cik":"0001597143","reported_name":"Clarus Lifesciences III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15492,"kind":"organization","name":"Clarus Ventures III GP, L.P.","position":2,"cik":"0001620148","reported_name":"Clarus Ventures III GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163261,"kind":"organization","name":"Clarus Ventures III, LLC","position":3,"cik":"0001664942","reported_name":"Clarus Ventures III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":4,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139654,"kind":"person","name":"GALAKATOS NICHOLAS","position":5,"cik":"0001252522","reported_name":"GALAKATOS NICHOLAS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":6,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":7,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74247,"kind":"person","name":"Requadt Scott","position":8,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":9,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-07-02T17:14:14.000Z","date":"2018-07-02","kind":"exercise","acquired":true,"shares":755780,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Clarus Ventures III GP, LP, or GPLP, as the sole general partner of Clarus Lifesciences III, LP, or Clarus, may be deemed to beneficially own certain of the shares held by Clarus. GPLP disclaims beneficial ownership of all shares held by Clarus in which the GPLP does not have a pecuniary interest. Clarus Ventures III, LLC, or GPLLC, as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. GPLLC disclaims beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest. Each of Dennis Henner, Nicholas Galakatos, Robert Liptak, Nicholas Simon, Scott Requadt and Kurt Wheeler, as individual managing directors of GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Dr. Henner and Messrs. Galakatos, Liptak, Simon, Requadt and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which they do not have an actual pecuniary interest."}],"balance_after":1694269,"source":{"system":"sec-edgar","filing":"0001209191-18-040426","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1667633/000120919118040426/doc4.xml","form_type":"4"}},{"id":3878861,"issuer":{"id":16035,"kind":"organization","name":"Forty Seven, Inc.","symbol":"FTSV"},"owners":[{"id":15491,"kind":"organization","name":"Clarus Lifesciences III, L.P.","position":1,"cik":"0001597143","reported_name":"Clarus Lifesciences III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15492,"kind":"organization","name":"Clarus Ventures III GP, L.P.","position":2,"cik":"0001620148","reported_name":"Clarus Ventures III GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163261,"kind":"organization","name":"Clarus Ventures III, LLC","position":3,"cik":"0001664942","reported_name":"Clarus Ventures III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":4,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139654,"kind":"person","name":"GALAKATOS NICHOLAS","position":5,"cik":"0001252522","reported_name":"GALAKATOS NICHOLAS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":6,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":7,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74247,"kind":"person","name":"Requadt Scott","position":8,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":9,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-07-02T17:14:14.000Z","date":"2018-07-02","kind":"exercise","acquired":true,"shares":938489,"ownership":{"direct":false,"nature":"See foonote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Clarus Ventures III GP, LP, or GPLP, as the sole general partner of Clarus Lifesciences III, LP, or Clarus, may be deemed to beneficially own certain of the shares held by Clarus. GPLP disclaims beneficial ownership of all shares held by Clarus in which the GPLP does not have a pecuniary interest. Clarus Ventures III, LLC, or GPLLC, as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. GPLLC disclaims beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest. Each of Dennis Henner, Nicholas Galakatos, Robert Liptak, Nicholas Simon, Scott Requadt and Kurt Wheeler, as individual managing directors of GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Dr. Henner and Messrs. Galakatos, Liptak, Simon, Requadt and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which they do not have an actual pecuniary interest."}],"balance_after":938489,"source":{"system":"sec-edgar","filing":"0001209191-18-040426","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1667633/000120919118040426/doc4.xml","form_type":"4"}},{"id":4090951,"issuer":{"id":3496,"kind":"organization","name":"GLOBUS MEDICAL INC","symbol":"GMED"},"owners":[{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":1,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy Class A Common Stock)","published_at":"2018-01-24T21:19:31.000Z","date":"2018-01-22","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest over a three-year period with one-twelfth (1/12) of the options granted vesting on March 31, 2018, and the balance of the options granted vesting ratably on a quarterly basis over the following 11 quarters."}],"balance_after":25000,"derivative":{"exercise_price":43.77,"expiration_date":"2028-01-22","underlying":"Class A Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-18-005101","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1237831/000120919118005101/doc4.xml","form_type":"4"}},{"id":4184776,"issuer":{"id":55304,"kind":"organization","name":"Venus Concept Inc.","symbol":"VERO"},"owners":[{"id":15989,"kind":"organization","name":"Clarus Lifesciences II, L.P.","position":1,"cik":"0001431443","reported_name":"Clarus Lifesciences II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15990,"kind":"organization","name":"Clarus Ventures II GP, L.P.","position":2,"cik":"0001431439","reported_name":"Clarus Ventures II GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163523,"kind":"organization","name":"Clarus Ventures II, LLC","position":3,"cik":"0001431437","reported_name":"Clarus Ventures II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139654,"kind":"person","name":"GALAKATOS NICHOLAS","position":4,"cik":"0001252522","reported_name":"GALAKATOS NICHOLAS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":5,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":6,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":7,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":8,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Promissory Note","published_at":"2017-10-17T18:43:06.000Z","date":"2017-10-16","kind":"exercise","acquired":false,"reported_value":1259269.79,"ownership":{"direct":true},"footnotes":[{"field":"reported_value","element":"transactionTotalValue","label":"F4","text":"The amount reported in column 5 is the principal amount of Reporting Person's Convertible Promissory Note (the \"Note\").  The outstanding principal and accrued interest of the Note automatically converted into shares of the Issuer's Common Stock at the price per share available to the public as set forth in the final prospectus related to the Issuer's IPO upon the closing of the IPO."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The amount reported in column 5 is the principal amount of Reporting Person's Convertible Promissory Note (the \"Note\").  The outstanding principal and accrued interest of the Note automatically converted into shares of the Issuer's Common Stock at the price per share available to the public as set forth in the final prospectus related to the Issuer's IPO upon the closing of the IPO."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The amount reported in column 5 is the principal amount of Reporting Person's Convertible Promissory Note (the \"Note\").  The outstanding principal and accrued interest of the Note automatically converted into shares of the Issuer's Common Stock at the price per share available to the public as set forth in the final prospectus related to the Issuer's IPO upon the closing of the IPO."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The amount reported in column 5 is the principal amount of Reporting Person's Convertible Promissory Note (the \"Note\").  The outstanding principal and accrued interest of the Note automatically converted into shares of the Issuer's Common Stock at the price per share available to the public as set forth in the final prospectus related to the Issuer's IPO upon the closing of the IPO."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are directly held by Clarus Lifesciences II, L.P. (\"Clarus\"). Clarus Ventures II GP, L.P. (the \"GPLP\"), as the sole general partner of Clarus, may be deemed to beneficially own certain of the shares held by Clarus.  Clarus Ventures II, LLC (the \"GPLLC\"), as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. Each of he GPLP and the GPLLC disclaim beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest."}],"balance_after":0,"derivative":{"exercise_price":7,"underlying":"Common Stock","underlying_shares":180881},"source":{"system":"sec-edgar","filing":"0001140361-17-038920","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1431443/000114036117038920/doc1.xml","form_type":"4"}},{"id":4184775,"issuer":{"id":55304,"kind":"organization","name":"Venus Concept Inc.","symbol":"VERO"},"owners":[{"id":15989,"kind":"organization","name":"Clarus Lifesciences II, L.P.","position":1,"cik":"0001431443","reported_name":"Clarus Lifesciences II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15990,"kind":"organization","name":"Clarus Ventures II GP, L.P.","position":2,"cik":"0001431439","reported_name":"Clarus Ventures II GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163523,"kind":"organization","name":"Clarus Ventures II, LLC","position":3,"cik":"0001431437","reported_name":"Clarus Ventures II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139654,"kind":"person","name":"GALAKATOS NICHOLAS","position":4,"cik":"0001252522","reported_name":"GALAKATOS NICHOLAS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":5,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":6,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":7,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":8,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2017-10-17T18:43:06.000Z","date":"2017-10-16","kind":"exercise","acquired":false,"shares":3389105,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering (the \"IPO\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering (the \"IPO\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering (the \"IPO\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The expiration date is not relevant to the conversion of these securities."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are directly held by Clarus Lifesciences II, L.P. (\"Clarus\"). Clarus Ventures II GP, L.P. (the \"GPLP\"), as the sole general partner of Clarus, may be deemed to beneficially own certain of the shares held by Clarus.  Clarus Ventures II, LLC (the \"GPLLC\"), as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. Each of he GPLP and the GPLLC disclaim beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3389105},"source":{"system":"sec-edgar","filing":"0001140361-17-038920","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1431443/000114036117038920/doc1.xml","form_type":"4"}},{"id":4184774,"issuer":{"id":55304,"kind":"organization","name":"Venus Concept Inc.","symbol":"VERO"},"owners":[{"id":15989,"kind":"organization","name":"Clarus Lifesciences II, L.P.","position":1,"cik":"0001431443","reported_name":"Clarus Lifesciences II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15990,"kind":"organization","name":"Clarus Ventures II GP, L.P.","position":2,"cik":"0001431439","reported_name":"Clarus Ventures II GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163523,"kind":"organization","name":"Clarus Ventures II, LLC","position":3,"cik":"0001431437","reported_name":"Clarus Ventures II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139654,"kind":"person","name":"GALAKATOS NICHOLAS","position":4,"cik":"0001252522","reported_name":"GALAKATOS NICHOLAS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":5,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":6,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":7,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":8,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-10-17T18:43:06.000Z","date":"2017-10-16","kind":"exercise","acquired":true,"shares":180881,"price":7,"value":1266167.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are directly held by Clarus Lifesciences II, L.P. (\"Clarus\"). Clarus Ventures II GP, L.P. (the \"GPLP\"), as the sole general partner of Clarus, may be deemed to beneficially own certain of the shares held by Clarus.  Clarus Ventures II, LLC (the \"GPLLC\"), as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. Each of he GPLP and the GPLLC disclaim beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest."}],"balance_after":3569986,"source":{"system":"sec-edgar","filing":"0001140361-17-038920","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1431443/000114036117038920/doc1.xml","form_type":"4"}},{"id":4184773,"issuer":{"id":55304,"kind":"organization","name":"Venus Concept Inc.","symbol":"VERO"},"owners":[{"id":15989,"kind":"organization","name":"Clarus Lifesciences II, L.P.","position":1,"cik":"0001431443","reported_name":"Clarus Lifesciences II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15990,"kind":"organization","name":"Clarus Ventures II GP, L.P.","position":2,"cik":"0001431439","reported_name":"Clarus Ventures II GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163523,"kind":"organization","name":"Clarus Ventures II, LLC","position":3,"cik":"0001431437","reported_name":"Clarus Ventures II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139654,"kind":"person","name":"GALAKATOS NICHOLAS","position":4,"cik":"0001252522","reported_name":"GALAKATOS NICHOLAS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":5,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":6,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":7,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":8,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-10-17T18:43:06.000Z","date":"2017-10-16","kind":"exercise","acquired":true,"shares":3389105,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering (the \"IPO\")."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are directly held by Clarus Lifesciences II, L.P. (\"Clarus\"). Clarus Ventures II GP, L.P. (the \"GPLP\"), as the sole general partner of Clarus, may be deemed to beneficially own certain of the shares held by Clarus.  Clarus Ventures II, LLC (the \"GPLLC\"), as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. Each of he GPLP and the GPLLC disclaim beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest."}],"balance_after":3389105,"source":{"system":"sec-edgar","filing":"0001140361-17-038920","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1431443/000114036117038920/doc1.xml","form_type":"4"}},{"id":4186578,"issuer":{"id":55304,"kind":"organization","name":"Venus Concept Inc.","symbol":"VERO"},"owners":[{"id":15989,"kind":"organization","name":"Clarus Lifesciences II, L.P.","position":1,"cik":"0001431443","reported_name":"Clarus Lifesciences II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15990,"kind":"organization","name":"Clarus Ventures II GP, L.P.","position":2,"cik":"0001431439","reported_name":"Clarus Ventures II GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163523,"kind":"organization","name":"Clarus Ventures II, LLC","position":3,"cik":"0001431437","reported_name":"Clarus Ventures II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":4,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":5,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139654,"kind":"person","name":"GALAKATOS NICHOLAS","position":6,"cik":"0001252522","reported_name":"GALAKATOS NICHOLAS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":7,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":8,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Promissory Note","published_at":"2017-10-13T19:04:52.000Z","date":"2017-10-11","kind":"other","acquired":true,"price":1259269.79,"reported_value":1259269.79,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The securities were originally acquired from the Issuer on September 6, 2017; however, the conversion price was set upon the pricing of the Issuer's Initial Public Offering (the \"IPO\")."},{"field":"reported_value","element":"transactionTotalValue","label":"F2","text":"The amount reported represents the principal amount of the Reporting Person's Convertible Promissory Note (the \"Note\") only. Accrued interest of 5% per year based on the actual number of days outstanding through the conversion date will also convert."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The amount reported represents the principal amount of the Reporting Person's Convertible Promissory Note (the \"Note\") only. Accrued interest of 5% per year based on the actual number of days outstanding through the conversion date will also convert."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The outstanding principal and accrued interest of the Note automatically converts into shares of the Issuer's Common Stock at the price per share available to the public as set forth in the final prospectus related to the IPO upon the closing of the IPO; if not so converted, the Note has a maturity date of September 6, 2018, at which time it will automatically convert into shares of the Issuer's capital stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The outstanding principal and accrued interest of the Note automatically converts into shares of the Issuer's Common Stock at the price per share available to the public as set forth in the final prospectus related to the IPO upon the closing of the IPO; if not so converted, the Note has a maturity date of September 6, 2018, at which time it will automatically convert into shares of the Issuer's capital stock."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The outstanding principal and accrued interest of the Note automatically converts into shares of the Issuer's Common Stock at the price per share available to the public as set forth in the final prospectus related to the IPO upon the closing of the IPO; if not so converted, the Note has a maturity date of September 6, 2018, at which time it will automatically convert into shares of the Issuer's capital stock."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F2","text":"The amount reported represents the principal amount of the Reporting Person's Convertible Promissory Note (the \"Note\") only. Accrued interest of 5% per year based on the actual number of days outstanding through the conversion date will also convert."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The convertible promissory note is directly held by Clarus Lifesciences II, L.P. (\"Clarus\"). Clarus Ventures II GP, L.P. (the \"GPLP\"), as the sole general partner of Clarus, may be deemed to beneficially own certain of the shares held by Clarus. Clarus Ventures II, LLC (the \"GPLLC\"), as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. Each of he GPLP and the GPLLC disclaim beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest."}],"derivative":{"exercise_price":7,"underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001140361-17-038670","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1431443/000114036117038670/doc1.xml","form_type":"4"}},{"id":4473333,"issuer":{"id":3496,"kind":"organization","name":"GLOBUS MEDICAL INC","symbol":"GMED"},"owners":[{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":1,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy Class A Common Stock)","published_at":"2017-02-01T21:10:05.000Z","date":"2017-01-30","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest over a three-year period with one-twelfth (1/12) of the options granted vesting on March 31, 2017, and the balance of the options granted vesting ratably on a quarterly basis over the following 11 quarters."}],"balance_after":25000,"derivative":{"exercise_price":26.27,"expiration_date":"2027-01-30","underlying":"Class A Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-17-006663","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1237831/000120919117006663/doc4.xml","form_type":"4"}}]}